menu
    • menu
    [{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Bill & Melinda Gates Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals for CAS-71-58-9

    Menu

    CAS-71-58-9

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pfizer Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Medroxyprogesterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Bill & Melinda Gates Foundation, Children’s Investment Fund Foundation, Pfizer and Becton, Dickinson & Compa...

                            Details : The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030.

                            Brand Name : Sayana Press

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 03, 2023

                            Lead Product(s) : Medroxyprogesterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth